Our results are consistent with the results of Sedlakova et al. [40] and Li et al. [39] who observed increased levels of VEGF in the group of ovarian cancer patients compared to the benign ovarian tumor patients, although the tested groups with non-malignant lesions were much smaller (15 and 25 women respectively). This evidence concerns the gene VEGFA and ovarian benign neoplasm.